In episode 428, Mike and James invite Barb Farrell to discuss all the great work being done by the people at deprescribing.org.  We discuss the general approach to deprescribing and why it is so important to keep this concept front and center of health discussions.

Show notes

In episode 427, James and Mike invite Mark McConnell back to the podcast to discuss the philosophy around how not to do what didn’t need to be done. You start with a differential diagnosis then think about what are the possible causes of this presentation?

In episode 426, James and Mike discuss in a PREMIUM way the first large RCT of the polypill. This single pill version contained aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan. Have a listen and find out what happened.

Show notes

In episode 425, James and Mike invite Samantha back again to talk about the evidence around the incidence of opioid use disorder that we cause by prescribing opioids. The key issue seems to be whether or not your patient has a history of substance abuse. 

Show notes

Tools For Practice

In episode 424, James and Mike continue chatting with Samantha Moe about a number of useful studies in primary care. We talk about blood pressures in the elderly, negative urine cultures, melatonin and migraine, dementia and driving, and complementary health products for the common cold.

Show notes

In episode 423, James and Mike welcome Samantha Moe, a pharmacist and clinical evidence expert with the College of Family Physicians, to the podcast. We discuss studies on cannabis and risk of schizophrenia, the harms of PPIs, H pylori infections and duration of treatment, and blood pressure measurements over clothes or a bare arm.

Show notes

In episode 422, James and Mike, go MEGA-PREMIUM and discuss the most recent meta-analysis (yes, yet another one) around the use of statins in older people. We then quickly review an article that looks at whether or not the guidelines for monitoring chronic conditions in primary care are evidence based.

In episode 421, Mike and James discuss the best available evidence around the newer and typically more expensive iron formulations used for iron deficiency anemia. We find the newer iron formulations are inferior to older ferrous salts when it comes to treating anemia and the evidence that newer formulations have less adverse effects is at best inconsistent.